Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Announces NOXCOVID Study Advances (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), announces that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the ...read more

Noxopharm Shareholder Update 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides this shareholder update as a summary of R&D progress in 2020 and a guide to what 2021 is expected to hol...read more

57% Reduction in Total Cholesterol from Nyradas NYX-PCSK9i In Vivo Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholestero...read more

Noxopharm Announces PreClinical Breakthrough Discovery Set to Expand Noxopharm Pipeline (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce what it regards as a major breakthrough in anti-cancer drug discovery. Noxopharm scientists h...read more

Noxopharm Completes A$23 million Placement to Fund Clinical Studies (ASX:NOX)

Highlights: - Noxopharm successfully raises A$23 million via a Placement, with cornerstone institutional investors coming from Australia, Hong Kong and the USA - Funds raised will drive two new ...read more

Noxopharm - Independent Discovery Validates DARRT Cancer Therapy (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to note that a recent discovery by a major U.S. university group significantly validates the Company’s...read more

Noxopharm - Veyonda To Be Tested In Combination With Opdivo In Trial (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that NOX have joined with Principal Investigator, Professor Paul De Souza, and three Sydney hosp...read more

Noxopharm Announces Dedicated Septic Shock Company Established (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce a partnership with Hudson Institute of Medical Research (‘Hudson Institute’) and a c...read more

Noxopharm - First COVID-19 Patient Treated in Veyonda Study (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the enrolment and treatment of the first patient into the Phase 1 NOXCOVID-1 study examini...read more

Noxopharm Announces Veyonda COVID-19 Study Approved For Immediate Start (ASX:NOX)

Australian drug development companyNoxopharm Limited (ASX: NOX) today announces the commencement of a clinical study of Veyonda® in COVID-19 patients. Following review by expert panels, official...read more

Noxopharm Announces Peer-Reviewed Publication Strengthens Case for Veyonda (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the publication of the first manuscript of the LuPIN trial in the journal, European Urology Onco...read more

Noxopharm Announces Data Shows Idronoxil Holds Key to Problem of COLD Cancers (ASX:NOX)

Important pre-clinical data from two independent research groups confirms that idronoxil (IDX), the active ingredient in Veyonda, achieves a major goal in restoring cancer-fighting immune function w...read more

Nyrada Brain Injury Drug Pharmacokinetic Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) reports results from a preclinical pharmacokinetic study of its two lead Brain Injury drug candidates. Both candidates have achieved durable therapeutic levels when administere...read more

Nyrada Cholesterol-Lowering Drug Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging preclinical results from its cholesterol-lowering program to develop a drug to treat hypercholesterolemia. A study using healthy donor human...read more

Noxopharm Announces COVID-19 Trial Program to Commence in Europe (ASX:NOX)

NOX announces commencement of its NOXCOVID clinical program with a planned Phase 1 trial in Europe. This action is designed to provide important safety data and proof-of-principle of Veyonda as a po...read more

Viewing: 91 - 105 of 200 Previous | Next